Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Madison S Salvitti

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The American Surgeon|December 26, 2022
Racial Differences and Injury Pattern Variation: Impact of COVID-19 on a Bronx Trauma CenterRisa N Kiernan, Madison S Salvitti, Gerard Baltazar, et al.
Carcinogenesis|May 13, 2022
CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat modelAshten N Omstead, Michael Paskewicz, Anastasia Gorbunova, et al.
Oncotarget|July 31, 2019
Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinomaLaila Babar, Juliann E Kosovec, Vida Jahangiri, et al.
Oncotarget|March 4, 2021
Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma modelAli H Zaidi, Ronan J Kelly, Anastasia Gorbunova, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The American Surgeon|December 26, 2022
Racial Differences and Injury Pattern Variation: Impact of COVID-19 on a Bronx Trauma CenterRisa N Kiernan, Madison S Salvitti, Gerard Baltazar, et al.
Carcinogenesis|May 13, 2022
CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat modelAshten N Omstead, Michael Paskewicz, Anastasia Gorbunova, et al.
Oncotarget|July 31, 2019
Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinomaLaila Babar, Juliann E Kosovec, Vida Jahangiri, et al.
Oncotarget|March 4, 2021
Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma modelAli H Zaidi, Ronan J Kelly, Anastasia Gorbunova, et al.
Pageof 1